<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347932</url>
  </required_header>
  <id_info>
    <org_study_id>433</org_study_id>
    <secondary_id>BOL-303224</secondary_id>
    <nct_id>NCT00347932</nct_id>
  </id_info>
  <brief_title>A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.</brief_title>
  <official_title>A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the
      treatment of bacterial conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Resolution of Baseline Bacterial Conjunctivitis</measure>
    <time_frame>Day 5 +/- 1 day</time_frame>
    <description>The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial Eradication of Baseline Bacterial Infection</measure>
    <time_frame>Day 5 +/- 1 day</time_frame>
    <description>Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution of Baseline Bacterial Conjunctivitis</measure>
    <time_frame>Day 8 or 9</time_frame>
    <description>The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Eradication of Baseline Bacterial Infection</measure>
    <time_frame>Day 8 or 9</time_frame>
    <description>Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">957</enrollment>
  <condition>Acute Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>ISV-403</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6% ISV-403 ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of ISV-403 ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-403</intervention_name>
    <description>Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.</description>
    <arm_group_label>ISV-403</arm_group_label>
    <other_name>besifloxacin</other_name>
    <other_name>Besivance</other_name>
    <other_name>BOL-303224</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a diagnosis of acute bacterial conjunctivitis and exhibit purulent
             conjunctival discharge and redness in at least one eye.

          -  Females of childbearing potential must utilized reliable contraceptive methods and
             have a negative pregnancy test.

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Known hypersensitivity to fluoroquinolones or to any of the study ingredients.

          -  Use of any antibiotic within 72 hours of treatment.

          -  Any disease or condition that could interfere with the safety and efficacy evaluations
             of the study medications.

          -  Participation in an ophthalmic drug or device research study within 30 days prior to
             entry into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Trusso</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <results_first_submitted>June 29, 2009</results_first_submitted>
  <results_first_submitted_qc>August 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2009</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled 6/5/2006, last patient exited on 11/7/2007. This study was conducted at multiple sites in the US.</recruitment_details>
      <pre_assignment_details>957 Subjects with bacterial conjunctivitis were randomized to receive besifloxacin ophthalmic suspension or its vehicle, 11 subjects were discontinued due to failure to meet enrollment criteria or used disallowed medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ISV-403</title>
          <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="475">As Randomized population - received at least one dose of study medication</participants>
                <participants group_id="P2" count="482">As Randomized Population - received at least one dose of study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ISV-403</title>
          <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="475"/>
            <count group_id="B2" value="482"/>
            <count group_id="B3" value="957"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 to 19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="475"/>
                    <measurement group_id="B2" value="482"/>
                    <measurement group_id="B3" value="957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Resolution of Baseline Bacterial Conjunctivitis</title>
        <description>The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection</description>
        <time_frame>Day 5 +/- 1 day</time_frame>
        <population>Modified intent to treat population, culture confirmed, as randomized</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Resolution of Baseline Bacterial Conjunctivitis</title>
          <description>The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection</description>
          <population>Modified intent to treat population, culture confirmed, as randomized</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Microbial Eradication of Baseline Bacterial Infection</title>
        <description>Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.</description>
        <time_frame>Day 5 +/- 1 day</time_frame>
        <population>Modified Intent to treat population, culture confirmed, as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbial Eradication of Baseline Bacterial Infection</title>
          <description>Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.</description>
          <population>Modified Intent to treat population, culture confirmed, as randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Resolution of Baseline Bacterial Conjunctivitis</title>
        <description>The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection</description>
        <time_frame>Day 8 or 9</time_frame>
        <population>Modified intent to treat population, culture confirmed, as randomized</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Resolution of Baseline Bacterial Conjunctivitis</title>
          <description>The absence (grade 0 on the ordinal scale) of ocular discharge and bulbar conjunctival injection</description>
          <population>Modified intent to treat population, culture confirmed, as randomized</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Eradication of Baseline Bacterial Infection</title>
        <description>Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.</description>
        <time_frame>Day 8 or 9</time_frame>
        <population>Modified intent to treat population, culture confirmed, as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbial Eradication of Baseline Bacterial Infection</title>
          <description>Absence (grade 0 on the ordinal scale) of all ocular bacterial species that were present at or above the threshold value for that species from the Cagle list at baseline.</description>
          <population>Modified intent to treat population, culture confirmed, as randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days</time_frame>
      <desc>Treatment emergent ocular adverse events occured in &lt; 5% of the patients</desc>
      <group_list>
        <group group_id="E1">
          <title>ISV-403</title>
          <description>Intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of intraocular 0.6% ISV-403 ophthalmic suspension administered three times daily to affected eyes for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="442"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="432"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="741"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="760"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has 45 days to review materials and provide comments back to the investigator.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Comstock</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(585) 338-6631</phone>
      <email>timothy.comstock@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

